GLPG - European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer Treatments | Benzinga
On Wednesday, BridGene Biosciences Inc. announced a strategic collaboration and licensing agreement with Galapagos NV (NASDAQ: GLPG).
Under the collaboration, BridGene will use its chemoproteomics platform, IMTAC, to discover novel small molecule drug candidates against the collaboration targets.
The parties will collaborate to advance the molecules to clinical candidates, which Galapagos has the exclusive rights to develop and commercialize.
The preclinical research collaboration will focus on oncology targets named by Galapagos.
Galapagos ...